Latest Market Entry News

Aeris Environmental Ltd reports strong Q1 FY26 growth, expanding its Syncromesh smart building platform into new sectors and international markets while maintaining solid financial discipline.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

Altech Batteries has launched immediate sales of sodium nickel chloride batteries through a strategic collaboration with AMPower, while advancing its flagship CERENERGY project in Germany with strong funding and prototype milestones.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

De.mem Limited has reported its second highest quarterly cash receipts alongside record revenues and EBITDA for Q3 2025, boosted by a key acquisition expanding its footprint in the gold mining sector.

SportsHero has launched its iGV Game Pass subscription in the Philippines through a strategic partnership with PLDT Home, tapping into a booming PC gaming market.

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Green Critical Minerals advances its Very High Density graphite technology with strong thermal performance validation, production scale-up, and strategic moves into global markets including a planned US listing.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.